# DAMAE Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/damae-medical

- Industry: Medical Devices & Equipment
- Headquarters: Paris, France
- Website: www.damaemedical.fr
- Total disclosed funding: $23M
- Latest round: Series B (Nov 26, 2025)
- Investors on record: 5

## About

DAMAE Medical specializes in non-invasive imaging solutions for skin cancer diagnosis, utilizing advanced technology to enhance diagnostic accuracy and treatment efficacy in dermatology.Founded in 2014 in Paris, France, DAMAE Medical develops innovative imaging solutions for dermatologists. The company raised EUR 15 million in Series B funding on Novemver 26, 2025, led by Creadev, with participation from Intesa SanPaolo Private Banking, BNP Paribas Developpement and Kurma Partners. Anaïs Barut serves as the CEO, and the company has completed 4 deals to date. Damae Medical specializes in advanced non-invasive imaging solutions for skin cancer diagnosis, primarily through its flagship product, deepLive™. This state-of-the-art medical device leverages Line-field Confocal Optical Coherence Tomography (LC-OCT) technology, offering high-resolution 3D imaging of various skin conditions. The deepLive™ system allows dermatologists to visualize skin lesions in a detailed, histology-like vertical mode and a confocal-like horizontal mode, enabling enhanced diagnostic accuracy, especially for melanoma and carcinoma. Launched in recent years, deepLive™ has been adopted in over 10 countries including major markets such as Europe, Japan, Australia, and the United States, serving hospitals, dermatology clinics, and healthcare professionals who prioritize efficient patient management and non-invasive procedures.Damae Medical’s revenue model is primarily built around the sale and deployment of the deepLive™ imaging systems. The company engages in direct sales to hospitals and dermatological clinics, where clients purchase the equipment outright, along with potential service contracts for ongoing maintenance and support. Additionally, Damae Medical may explore partnerships with healthcare providers to facilitate access to its technology, thereby enhancing patient care and diagnostic capabilities. While specific pricing structures for the deepLive™ system and associated services are not disclosed, the company's financial growth is underpinned by strategic investments and the increasing demand for innovative diagnostic tools in the skin cancer detection space.In November 2025, DAMAE Medical raised EUR 15 million in Series B funding, which will be allocated to widen access to deepLive, grow its sales and clinical support teams, boost its production capabilities, and advance AI tools for more skin diseases

## Funding rounds

- Series B, Nov 26, 2025, $17M — Kurma Partners, Intesa SanPaolo Private Banking, Creadev, BNP Paribas Developpement
- Series A, Oct 19, 2021, $5.8M — Kurma Partners, Paris-Saclay Seed Fund, BNP Paribas Developpement

## Investors

- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A, Series B
- Paris-Saclay Seed Fund (https://capitalatlas.ai/funds/paris-saclay-seed-fund) — Series A
- BNP Paribas Developpement (https://capitalatlas.ai/funds/bnp-paribas-developpement) — Series A, Series B
- Intesa SanPaolo Private Banking — Series B
- Creadev — Series B